Department of Urology, Academic Medical Center, P.O. box 22660, 1100 DD, Amsterdam, The Netherlands.
World J Urol. 2011 Aug;29(4):503-9. doi: 10.1007/s00345-011-0659-2. Epub 2011 Feb 25.
To investigate whether narrow band imaging (NBI)-assisted transurethral resection (TUR) (NBI-TUR) has an impact on non-muscle invasive bladder cancer (NMIBC) residual tumour rate compared to white light (WL)-assisted TUR (WL-TUR).
Patients with NMIBC treated with either NBI- or WL-TUR were compared in a frequency-matched index-control setting. During NBI-TUR, all suspicious lesions identified by either WL or NBI were resected. Index patients (NBI-TUR, n = 40) were prospectively recruited and control patients (WL-TUR, n = 120) were retrospectively collected, whilst being blinded for their first follow-up (fFU)-status. Non-radical TUR cases, patients without evidence of urothelial carcinoma in the pathology specimen and those with isolated carcinoma in situ or muscle invasive disease were excluded. Matching was based on the risk of tumour recurrence defined by (a) the EORTC risk score for recurrence and (b) the administration or not of one single chemotherapeutic intravesical instillation immediately after TUR. All patients underwent routine follow-up with WL cystoscopy supplemented with cytology at 3 months or re-TUR in selected cases. The residual tumour rates at fFU (RR-fFU) of patients with NMIBC submitted to either NBI- or WL-TUR were compared.
Baseline patient and tumour characteristics were comparable between groups. The RR-fFU for WL- and NBI-TUR was 30.5% (36 out of 118 patients) and 15.0% (6 out of 40 patients), respectively (OR: 2.7, one-sided 95% CI: 1.2-6.1; P = 0.03).
NBI-TUR decreases residual tumour rate significantly when compared to a matched cohort of WL-TUR.
研究窄带成像(NBI)辅助经尿道切除术(TUR)(NBI-TUR)与白光(WL)辅助 TUR(WL-TUR)相比,对非肌肉浸润性膀胱癌(NMIBC)残留肿瘤率的影响。
采用频数匹配的病例对照研究,比较接受 NBI-TUR 或 WL-TUR 治疗的 NMIBC 患者。在 NBI-TUR 中,所有通过 WL 或 NBI 识别的可疑病变均被切除。前瞻性招募指数患者(NBI-TUR,n=40),并回顾性收集对照患者(WL-TUR,n=120),但对其首次随访(FU)的状态不知情。排除非根治性 TUR 病例、病理标本中无尿路上皮癌证据的患者,以及孤立的原位癌或肌层浸润性疾病患者。匹配基于肿瘤复发风险,由(a)EORTC 复发风险评分和(b)TUR 后是否给予单次膀胱内化疗来定义。所有患者均接受常规随访,包括 WL 膀胱镜检查和 3 个月时的细胞学检查,或在选定病例中进行再 TUR。比较接受 NBI-TUR 或 WL-TUR 的 NMIBC 患者的 FU 时的残留肿瘤率(RR-FU)。
两组患者的基线特征和肿瘤特征相似。WL-TUR 和 NBI-TUR 的 RR-FU 分别为 30.5%(118 例患者中的 36 例)和 15.0%(40 例患者中的 6 例)(OR:2.7,单侧 95%CI:1.2-6.1;P=0.03)。
与匹配的 WL-TUR 队列相比,NBI-TUR 显著降低了残留肿瘤率。